MANIPALHOSLLOYDSENGG+6
When Consolidation Meets Opportunity—The August M&A Burst Across Infra, Healthcare, and Manufacturing
M&A · consolidation · strategic acquisitions
ResearchDeep dive6 minIndustrials & Infra
Research Reports
Independent research on listed companies — quarterly result analysis, earnings call verdicts and sector notes, written up in full.
Latest coverage
Today
Yesterday
FREDUNFredun Pharmaceuticals Ltd
The 90% Quarter That Rewrites 30% Growth
earnings · growth · guidance
FREDUNFredun Pharmaceuticals Ltd
Strong Q1 delivery with raised FY27 guidance; margin timeline uncertain
revenue growth · new-age brands · geographic expansion
ZIMLABZim Laboratories Ltd
Best quarter in years masks a loss-making quarter; EU bet remains unproven
EU-GMP reinstatement · loss-making growth · margin compression
ZIMLABZim Laboratories Ltd
Loss-making quarter masks EU-GMP bet; profitability path unproven
EU-GMP remediation · NIP/OTF pipeline · regulated markets
LUPINLUPIN LTD.
Lupin's CNS Anchor—When Pitolisant Approval Meets Competitive Generic Density
USFDA approval · Pitolisant · CNS drugs
ResearchDeep dive5 minPharma & Healthcare
WINDLASWindlas Biotech Ltd
Record revenue, flat profit—the ESOP mask and the Plant 6 pivot
CDMO · Trade Generics · Plant 6
WINDLASWindlas Biotech Ltd
Record revenue, flat profit; Plant 6 catalyst ahead
14 consecutive quarters · CDMO 29% growth · TGx stagnant
AHCLAnlon Healthcare Ltd
The ₹87.6 Crore Growth Story That Isn't—Organic Anlon Is Flat
margin collapse · acquisition dependency · organic stagnation
AHCLAnlon Healthcare Ltd
Strong revenue beat, EBITDA miss; margin recovery critical
acquisition-led growth · margin pressure · raw material inflation
IPCALABIPCA LABORATORIES LTD.
Headline Beat, Organic Softer: Material Costs Rising
earnings beat · organic growth · material costs
IPCALABIPCA LABORATORIES LTD.
Beat Q1 sharply, FY27 guide raised 2-3pp; material costs rising
Revenue +21% · Guide raised · Biotech 7-pipeline
JAGSNPHARMJAGSONPAL PHARMACEUTICALS LTD.
Operations Shine, But Revenue Can't Hit the Full-Year Target at This Pace
earnings review · revenue guidance · Aequitas acquisition
JAGSNPHARMJAGSONPAL PHARMACEUTICALS LTD.
Growth soft vs guidance; Aequitas entry strategic but margins thin
brand_led_growth · semi_chronic_shift · aequitas_acquisition
GPTHEALTHGPT Healthcare Ltd
YoY beat, but momentum stumbles — Raipur loss and sequential decline raise execution concerns
earnings review · sequential weakness · Raipur profitability
GPTHEALTHGPT Healthcare Ltd
Beat YoY growth, but sequential PAT decline signals momentum loss
specialty mix ARPOB · Raipur unprofitable · sequential decline
SHILPAMEDSHILPA MEDICARE LTD.
The ₹28 Crore Mask: Transformation Real, Execution Risky
earnings · transformation · CDMO
SHILPAMEDSHILPA MEDICARE LTD.
Strong topline, margin compression, pipeline-rich transformation story
CDMO · Formulation launches · Biologics scaling
INNOVACAPInnova Captab Ltd
Volume Beat, Guidance Held — the Jammu Story Stays Multi-Year
CDMO · Jammu facility · volume growth
INNOVACAPInnova Captab Ltd
Volume target hit, margins stable, Jammu ramp on track
volume growth · CDMO demand · Jammu ramp
HIKALHIKAL LTD.
Recovery On Track, But Leverage and Crop Headwinds Cloud the Outlook
FDA remediation · leverage drag · Pharma CDMO
HIKALHIKAL LTD.
Pharma recovery on track; near-term earnings under pressure
FDA remediation · Animal Health scaling · CDMO partnerships
AARTIDRUGSAARTI DRUGS LTD.
Revenue up 19%, profit down 7%: the pricing illusion
pricing power · volume miss · capacity ramp
AARTIDRUGSAARTI DRUGS LTD.
Pricing surge masks weak volume; margin gains at risk if war-driven tailwinds fade
pricing power · capacity ramp-up · volume miss
HCGHealthCare Global Enterprises Ltd
Margin beat hinges on mix, not pricing — ARPP stalls at +2%
HCG · oncology · ARPP stagnation
HCGHealthCare Global Enterprises Ltd
Strong margins, volume-driven growth, strategic clarity—but ARPP weakness and new-hospital drag remain
payor mix · EBITDA margin expansion · volume growth
VIJAYAVijaya Diagnostic Centre Ltd
The ₹190 Crore Question: Execution Strong, But Capex Tests Margins
diagnostics · capex expansion · tier-2
VIJAYAVijaya Diagnostic Centre Ltd
Strong execution, capex raised on expansion confidence
network expansion · margin resilience · B2C leverage
Sun, 16 Aug
